disulfiram has been researched along with Brain Neoplasms in 27 studies
Brain Neoplasms: Neoplasms of the intracranial components of the central nervous system, including the cerebral hemispheres, basal ganglia, hypothalamus, thalamus, brain stem, and cerebellum. Brain neoplasms are subdivided into primary (originating from brain tissue) and secondary (i.e., metastatic) forms. Primary neoplasms are subdivided into benign and malignant forms. In general, brain tumors may also be classified by age of onset, histologic type, or presenting location in the brain.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Preclinical studies have suggested promising activity for the combination of disulfiram and copper (DSF/Cu) against glioblastoma (GBM) including re-sensitization to temozolomide (TMZ)." | 9.30 | A multicenter phase II study of temozolomide plus disulfiram and copper for recurrent temozolomide-resistant glioblastoma. ( Boockvar, J; Campian, JL; Chaudhary, R; Chinnaiyan, P; Cohen, AL; Fink, K; Goldlust, S; Huang, J; Marcus, S; Wan, L, 2019) |
| "Disulfiram has shown promising activity including proteasome inhibitory properties and synergy with temozolomide in preclinical glioblastoma (GBM) models." | 9.27 | Final results of a phase I dose-escalation, dose-expansion study of adding disulfiram with or without copper to adjuvant temozolomide for newly diagnosed glioblastoma. ( Ansstas, G; Campian, JL; DeWees, TA; Gujar, AD; Huang, J; Kim, AH; Lockhart, AC; Tran, DD; Tsien, C, 2018) |
| " Development strategies using molecular encapsulation of DS and the parenteral dosage forms improve the anticancer pharmacology of the drug." | 7.01 | Clinical, pharmacological, and formulation evaluation of disulfiram in the treatment of glioblastoma - a systematic literature review. ( Benkő, BM; Lamprou, DA; Sebe, I; Sebestyén, A; Zelkó, R, 2023) |
| "Hypoxia is one of the determinants of GSC." | 5.72 | PLGA-Nano-Encapsulated Disulfiram Inhibits Hypoxia-Induced NF-κB, Cancer Stem Cells, and Targets Glioblastoma In Vitro and In Vivo. ( Armesilla, AL; Azar, K; Bian, XW; Kannappan, V; Kilari, RS; Kurusamy, S; Liu, P; Liu, Y; Morris, MR; Najlah, M; Wang, W; Wang, Z, 2022) |
| "Cells from brain tumors with high aldehyde dehydrogenase (ALDH) activity have a number of characteristics that are similar to brain tumor initiating cells (BTICs)." | 5.42 | Disulfiram modulates stemness and metabolism of brain tumor initiating cells in atypical teratoid/rhabdoid tumors. ( Choi, JW; Choi, SA; Eum, D; Kim, IH; Kim, SK; Lee, JY; Park, KD; Park, SH; Phi, JH; Wang, KC, 2015) |
| "These brain tumors are often resistant to chemotherapies like temozolomide (TMZ) and there are very few treatment options available to patients." | 5.38 | Disulfiram, a drug widely used to control alcoholism, suppresses the self-renewal of glioblastoma and over-rides resistance to temozolomide. ( Berns, R; Dunn, SE; Fotovati, A; Hu, K; Kast, RE; Kong, E; Lee, C; Luk, M; Pambid, M; Toyota, B; Toyota, E; Triscott, J; Yip, S, 2012) |
| "Preclinical studies have suggested promising activity for the combination of disulfiram and copper (DSF/Cu) against glioblastoma (GBM) including re-sensitization to temozolomide (TMZ)." | 5.30 | A multicenter phase II study of temozolomide plus disulfiram and copper for recurrent temozolomide-resistant glioblastoma. ( Boockvar, J; Campian, JL; Chaudhary, R; Chinnaiyan, P; Cohen, AL; Fink, K; Goldlust, S; Huang, J; Marcus, S; Wan, L, 2019) |
| "Disulfiram has shown promising activity including proteasome inhibitory properties and synergy with temozolomide in preclinical glioblastoma (GBM) models." | 5.27 | Final results of a phase I dose-escalation, dose-expansion study of adding disulfiram with or without copper to adjuvant temozolomide for newly diagnosed glioblastoma. ( Ansstas, G; Campian, JL; DeWees, TA; Gujar, AD; Huang, J; Kim, AH; Lockhart, AC; Tran, DD; Tsien, C, 2018) |
| "Constructed from a theoretical framework, the coordinated undermining of survival paths in glioblastoma (GBM) is a combination of nine drugs approved for non-oncological indications (CUSP9; aprepitant, auranofin, captopril, celecoxib, disulfiram, itraconazole, minocycline, quetiapine, and sertraline) combined with temozolomide (TMZ)." | 3.91 | The efficacy of a coordinated pharmacological blockade in glioblastoma stem cells with nine repurposed drugs using the CUSP9 strategy. ( Grieg, Z; Langmoen, IA; Sandberg, CJ; Skaga, E; Skaga, IØ; Vik-Mo, EO, 2019) |
| " Development strategies using molecular encapsulation of DS and the parenteral dosage forms improve the anticancer pharmacology of the drug." | 3.01 | Clinical, pharmacological, and formulation evaluation of disulfiram in the treatment of glioblastoma - a systematic literature review. ( Benkő, BM; Lamprou, DA; Sebe, I; Sebestyén, A; Zelkó, R, 2023) |
| "Among the different types of brain tumors, glioblastoma (GBM) is considered the most aggressive and remains extremely difficult to treat." | 2.52 | Concise review: bullseye: targeting cancer stem cells to improve the treatment of gliomas by repurposing disulfiram. ( Dunn, SE; Rose Pambid, M; Triscott, J, 2015) |
| "Hypoxia is one of the determinants of GSC." | 1.72 | PLGA-Nano-Encapsulated Disulfiram Inhibits Hypoxia-Induced NF-κB, Cancer Stem Cells, and Targets Glioblastoma In Vitro and In Vivo. ( Armesilla, AL; Azar, K; Bian, XW; Kannappan, V; Kilari, RS; Kurusamy, S; Liu, P; Liu, Y; Morris, MR; Najlah, M; Wang, W; Wang, Z, 2022) |
| "Cells from brain tumors with high aldehyde dehydrogenase (ALDH) activity have a number of characteristics that are similar to brain tumor initiating cells (BTICs)." | 1.42 | Disulfiram modulates stemness and metabolism of brain tumor initiating cells in atypical teratoid/rhabdoid tumors. ( Choi, JW; Choi, SA; Eum, D; Kim, IH; Kim, SK; Lee, JY; Park, KD; Park, SH; Phi, JH; Wang, KC, 2015) |
| "These brain tumors are often resistant to chemotherapies like temozolomide (TMZ) and there are very few treatment options available to patients." | 1.38 | Disulfiram, a drug widely used to control alcoholism, suppresses the self-renewal of glioblastoma and over-rides resistance to temozolomide. ( Berns, R; Dunn, SE; Fotovati, A; Hu, K; Kast, RE; Kong, E; Lee, C; Luk, M; Pambid, M; Toyota, B; Toyota, E; Triscott, J; Yip, S, 2012) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (3.70) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (7.41) | 29.6817 |
| 2010's | 20 (74.07) | 24.3611 |
| 2020's | 4 (14.81) | 2.80 |
| Authors | Studies |
|---|---|
| Serra, R | 1 |
| Zhao, T | 1 |
| Huq, S | 1 |
| Gorelick, NL | 1 |
| Casaos, J | 1 |
| Cecia, A | 1 |
| Mangraviti, A | 1 |
| Eberhart, C | 1 |
| Bai, R | 1 |
| Olivi, A | 1 |
| Brem, H | 1 |
| Jackson, EM | 1 |
| Tyler, B | 1 |
| Kannappan, V | 3 |
| Liu, Y | 1 |
| Wang, Z | 1 |
| Azar, K | 1 |
| Kurusamy, S | 1 |
| Kilari, RS | 1 |
| Armesilla, AL | 3 |
| Morris, MR | 1 |
| Najlah, M | 1 |
| Liu, P | 3 |
| Bian, XW | 1 |
| Wang, W | 7 |
| Benkő, BM | 1 |
| Lamprou, DA | 1 |
| Sebestyén, A | 1 |
| Zelkó, R | 1 |
| Sebe, I | 1 |
| Jangra, A | 1 |
| Choi, SA | 3 |
| Yang, J | 1 |
| Koh, EJ | 1 |
| Phi, JH | 3 |
| Lee, JY | 3 |
| Wang, KC | 3 |
| Kim, SK | 4 |
| Lee, YE | 1 |
| Kwack, PA | 1 |
| Kim, HJ | 2 |
| Kim, IH | 3 |
| Chong, S | 1 |
| Park, SH | 2 |
| Park, KD | 2 |
| Hwang, DW | 1 |
| Joo, KM | 1 |
| Huang, J | 2 |
| Campian, JL | 2 |
| Gujar, AD | 1 |
| Tsien, C | 1 |
| Ansstas, G | 1 |
| Tran, DD | 1 |
| DeWees, TA | 1 |
| Lockhart, AC | 1 |
| Kim, AH | 1 |
| Mettang, M | 1 |
| Meyer-Pannwitt, V | 1 |
| Karpel-Massler, G | 3 |
| Zhou, S | 1 |
| Carragher, NO | 1 |
| Föhr, KJ | 1 |
| Baumann, B | 1 |
| Nonnenmacher, L | 1 |
| Enzenmüller, S | 1 |
| Dahlhaus, M | 1 |
| Siegelin, MD | 1 |
| Stroh, S | 1 |
| Mertens, D | 1 |
| Fischer-Posovszky, P | 1 |
| Schneider, EM | 1 |
| Halatsch, ME | 4 |
| Debatin, KM | 1 |
| Westhoff, MA | 1 |
| Koh, HK | 1 |
| Seo, SY | 1 |
| Kim, JH | 1 |
| Chie, EK | 1 |
| Chaudhary, R | 1 |
| Cohen, AL | 1 |
| Fink, K | 1 |
| Goldlust, S | 1 |
| Boockvar, J | 1 |
| Chinnaiyan, P | 1 |
| Wan, L | 1 |
| Marcus, S | 1 |
| Skaga, E | 1 |
| Skaga, IØ | 1 |
| Grieg, Z | 1 |
| Sandberg, CJ | 1 |
| Langmoen, IA | 1 |
| Vik-Mo, EO | 1 |
| Darling, JL | 3 |
| Kast, RE | 5 |
| Boockvar, JA | 1 |
| Brüning, A | 1 |
| Cappello, F | 1 |
| Chang, WW | 1 |
| Cvek, B | 2 |
| Dou, QP | 1 |
| Duenas-Gonzalez, A | 1 |
| Efferth, T | 1 |
| Focosi, D | 1 |
| Ghaffari, SH | 1 |
| Ketola, K | 1 |
| Khoshnevisan, A | 1 |
| Keizman, D | 1 |
| Magné, N | 1 |
| Marosi, C | 1 |
| McDonald, K | 1 |
| Muñoz, M | 1 |
| Paranjpe, A | 2 |
| Pourgholami, MH | 1 |
| Sardi, I | 1 |
| Sella, A | 1 |
| Srivenugopal, KS | 2 |
| Tuccori, M | 1 |
| Wirtz, CR | 1 |
| Zhang, R | 1 |
| Ali-Osman, F | 1 |
| Bobustuc, GC | 1 |
| Choi, JW | 1 |
| Eum, D | 1 |
| Zembko, I | 1 |
| Ahmed, I | 1 |
| Farooq, A | 1 |
| Dail, J | 1 |
| Tawari, P | 2 |
| Mcconville, C | 2 |
| Triscott, J | 2 |
| Rose Pambid, M | 1 |
| Dunn, SE | 2 |
| Belda-Iniesta, C | 1 |
| Brown, S | 2 |
| Goktug, T | 1 |
| Channathodiyil, P | 2 |
| Hugnot, JP | 1 |
| Guichet, PO | 1 |
| Bian, X | 1 |
| Lee, C | 1 |
| Hu, K | 1 |
| Fotovati, A | 1 |
| Berns, R | 1 |
| Pambid, M | 1 |
| Luk, M | 1 |
| Kong, E | 1 |
| Toyota, E | 1 |
| Yip, S | 1 |
| Toyota, B | 1 |
| Hothi, P | 1 |
| Martins, TJ | 1 |
| Chen, L | 1 |
| Deleyrolle, L | 1 |
| Yoon, JG | 1 |
| Reynolds, B | 1 |
| Foltz, G | 1 |
| Marikovsky, M | 1 |
| Nevo, N | 1 |
| Vadai, E | 1 |
| Harris-Cerruti, C | 1 |
| Goldstein, M | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase II, Multicenter, Open-Label, Single-Arm Study to Evaluate the Safety, Tolerability, and Efficacy of DIsulfiram and Copper Gluconate in Recurrent Glioblastoma[NCT03034135] | Phase 2 | 23 participants (Actual) | Interventional | 2017-03-09 | Completed | ||
| DIRECT (DIsulfiram REsponse as add-on to ChemoTherapy in Recurrent) Glioblastoma: A Randomized Controlled Trial[NCT02678975] | Phase 2/Phase 3 | 88 participants (Actual) | Interventional | 2017-01-31 | Completed | ||
| Randomized Phase 2 Trial of Treatment of Advanced Non Small Cell Lung Carcinoma With/Without Disulfiram and Cisplatin Navelbine[NCT00312819] | Phase 2/Phase 3 | 60 participants (Anticipated) | Interventional | 2006-03-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Duration of overall survival for patients that are alive (NCT03034135)
Timeframe: 14 months
| Intervention | months (Median) |
|---|---|
| DSF-Cu | 7.1 |
Duration of progression free survival according to RANO criteria (NCT03034135)
Timeframe: 12 months
| Intervention | months (Median) |
|---|---|
| DSF-Cu | 1.7 |
Number of Participants with Grade 3 and 4 serious adverse events (NCT03034135)
Timeframe: 14 months
| Intervention | Participants (Count of Participants) |
|---|---|
| DSF-Cu | 2 |
Percentage of patients that are free from progressive disease per RANO criteria (NCT03034135)
Timeframe: 6 months
| Intervention | percentage of participants (Number) |
|---|---|
| DSF-Cu | 14 |
ORR will be defined as the percentage of patients with complete response (CR) or partial response (PR) according to the RANO criteria. (NCT03034135)
Timeframe: 6 months
| Intervention | Participants (Count of Participants) | |
|---|---|---|
| Complete response | Partial Response | |
| DSF-Cu | 0 | 0 |
Percentage of patients that are alive (NCT03034135)
Timeframe: 6 months and 12 months
| Intervention | percentage of participants (Number) | |
|---|---|---|
| 6 months | 12 months | |
| DSF-Cu | 61 | 35 |
5 reviews available for disulfiram and Brain Neoplasms
| Article | Year |
|---|---|
Clinical, pharmacological, and formulation evaluation of disulfiram in the treatment of glioblastoma - a systematic literature review.
Topics: Brain; Brain Neoplasms; Disulfiram; Drug Delivery Systems; Glioblastoma; Humans | 2023 |
A conceptually new treatment approach for relapsed glioblastoma: coordinated undermining of survival paths with nine repurposed drugs (CUSP9) by the International Initiative for Accelerated Improvement of Glioblastoma Care.
Topics: Antineoplastic Combined Chemotherapy Protocols; Aprepitant; Artemisinins; Auranofin; Brain Neoplasms | 2013 |
Concise review: bullseye: targeting cancer stem cells to improve the treatment of gliomas by repurposing disulfiram.
Topics: Animals; Brain Neoplasms; Clinical Trials as Topic; Disulfiram; Drug Delivery Systems; Drug Repositi | 2015 |
Matrix metalloproteinase-2 and -9 in glioblastoma: a trio of old drugs-captopril, disulfiram and nelfinavir-are inhibitors with potential as adjunctive treatments in glioblastoma.
Topics: Angiotensin-Converting Enzyme Inhibitors; Brain Neoplasms; Captopril; Chemotherapy, Adjuvant; Disulf | 2012 |
Brain research and violent behavior. A summary and evaluation of the status of biomedical research on brain and aggressive violent behavior.
Topics: Aggression; Animals; Anticonvulsants; Antidepressive Agents; Behavior, Animal; Bipolar Disorder; Bra | 1974 |
2 trials available for disulfiram and Brain Neoplasms
| Article | Year |
|---|---|
Final results of a phase I dose-escalation, dose-expansion study of adding disulfiram with or without copper to adjuvant temozolomide for newly diagnosed glioblastoma.
Topics: Adjuvants, Immunologic; Adult; Aged; Antineoplastic Agents; Brain Neoplasms; Cohort Studies; Copper; | 2018 |
A multicenter phase II study of temozolomide plus disulfiram and copper for recurrent temozolomide-resistant glioblastoma.
Topics: Acetaldehyde Dehydrogenase Inhibitors; Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplasti | 2019 |
20 other studies available for disulfiram and Brain Neoplasms
| Article | Year |
|---|---|
Disulfiram and copper combination therapy targets NPL4, cancer stem cells and extends survival in a medulloblastoma model.
Topics: Aldehyde Dehydrogenase; Animals; Apoptosis; Brain Neoplasms; Cell Cycle; Cell Proliferation; Copper; | 2021 |
PLGA-Nano-Encapsulated Disulfiram Inhibits Hypoxia-Induced NF-κB, Cancer Stem Cells, and Targets Glioblastoma In Vitro and In Vivo.
Topics: Animals; Brain Neoplasms; Cell Line, Tumor; Disulfiram; Glioblastoma; Humans; Hypoxia; Mice; Neoplas | 2022 |
Disulfiram potentiates the anticancer effect of cisplatin in atypical teratoid/rhabdoid tumors (AT/RT).
Topics: Activating Transcription Factor 3; Aldehyde Dehydrogenase; Animals; Brain Neoplasms; Cell Line, Tumo | 2020 |
Repositioning disulfiram as a radiosensitizer against atypical teratoid/rhabdoid tumor.
Topics: Animals; Apoptosis; Brain Neoplasms; Cell Cycle Checkpoints; Cell Proliferation; Disulfiram; Humans; | 2017 |
Blocking distinct interactions between Glioblastoma cells and their tissue microenvironment: A novel multi-targeted therapeutic approach.
Topics: Acetaldehyde Dehydrogenase Inhibitors; Animals; Anti-Ulcer Agents; Apoptosis; Brain Neoplasms; Carbe | 2018 |
Disulfiram, a Re-positioned Aldehyde Dehydrogenase Inhibitor, Enhances Radiosensitivity of Human Glioblastoma Cells In Vitro.
Topics: Acetaldehyde Dehydrogenase Inhibitors; Brain Neoplasms; Caspase 3; Cell Cycle; Cell Line, Tumor; Dis | 2019 |
The efficacy of a coordinated pharmacological blockade in glioblastoma stem cells with nine repurposed drugs using the CUSP9 strategy.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Aprepitant; Auranofin; Brain Neoplasms; Cap | 2019 |
How could a drug used to treat alcoholism also be effective against glioblastoma?
Topics: Alcohol Deterrents; Alcoholism; Antineoplastic Agents; Blood-Brain Barrier; Brain Neoplasms; Disulfi | 2013 |
Disulfiram is a direct and potent inhibitor of human O6-methylguanine-DNA methyltransferase (MGMT) in brain tumor cells and mouse brain and markedly increases the alkylating DNA damage.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain; Brain Neoplasms; Cell Line, Tumor; Disulfiram; DN | 2014 |
CUSP9* treatment protocol for recurrent glioblastoma: aprepitant, artesunate, auranofin, captopril, celecoxib, disulfiram, itraconazole, ritonavir, sertraline augmenting continuous low dose temozolomide.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Aprepitant; Artemisinins; Artesunate; Auran | 2014 |
Disulfiram modulates stemness and metabolism of brain tumor initiating cells in atypical teratoid/rhabdoid tumors.
Topics: Acetaldehyde Dehydrogenase Inhibitors; Aldehyde Dehydrogenase; Animals; Antineoplastic Agents; Apopt | 2015 |
Development of disulfiram-loaded poly(lactic-co-glycolic acid) wafers for the localised treatment of glioblastoma multiforme: a comparison of manufacturing techniques.
Topics: Antineoplastic Agents; Brain Neoplasms; Calorimetry, Differential Scanning; Cell Line, Tumor; Cell S | 2015 |
Hot melt extruded and injection moulded disulfiram-loaded PLGA millirods for the treatment of glioblastoma multiforme via stereotactic injection.
Topics: Brain Neoplasms; Cell Line, Tumor; Disulfiram; Drug Carriers; Drug Delivery Systems; Freezing; Gliob | 2015 |
Suppressing glioblastoma stem cell function by aldehyde dehydrogenase inhibition with chloramphenicol or disulfiram as a new treatment adjunct: an hypothesis.
Topics: Aldehyde Dehydrogenase; Animals; Brain Neoplasms; Cell Differentiation; Cell Division; Chemotherapy, | 2009 |
Cytotoxic effect of disulfiram/copper on human glioblastoma cell lines and ALDH-positive cancer-stem-like cells.
Topics: Aldehyde Dehydrogenase; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Copper; Cytotoxicity, Immunolo | 2012 |
Disulfiram, a drug widely used to control alcoholism, suppresses the self-renewal of glioblastoma and over-rides resistance to temozolomide.
Topics: Alcohol Deterrents; Antineoplastic Agents, Alkylating; Apoptosis; Blotting, Western; Brain Neoplasms | 2012 |
High-throughput chemical screens identify disulfiram as an inhibitor of human glioblastoma stem cells.
Topics: Alcohol Deterrents; Animals; Apoptosis; Blotting, Western; Brain Neoplasms; Cell Proliferation; Disu | 2012 |
Comment on 'cytotoxic effect of disulfiram/copper on human glioblastoma cell lines and ALDH-positive cancer-stem-like cells'.
Topics: Aldehyde Dehydrogenase; Brain Neoplasms; Copper; Disulfiram; Glioblastoma; Humans; Neoplastic Stem C | 2013 |
Reply: Cytotoxic effect of disulfiram/copper on human glioblastoma cell lines and ALDH-positive cancer-stem-like cells.
Topics: Aldehyde Dehydrogenase; Brain Neoplasms; Copper; Disulfiram; Glioblastoma; Humans; Neoplastic Stem C | 2013 |
Cu/Zn superoxide dismutase plays a role in angiogenesis.
Topics: Animals; Apoptosis; Brain Neoplasms; Carcinoma, Lewis Lung; Disulfiram; Endothelium, Vascular; Enzym | 2002 |